Technology | April 08, 2011

Compact Camera Designed to Maximize Revenues and Efficiency

April 8, 2011 – The U.S. Food and Drug Administration (FDA) has cleared a next-generation compact gamma camera. MedX’s T-Quest includes enhanced thyroid imaging and features expanded imaging capabilities to perform parathyroid, sentinel node, MUGA, gastric emptying, hepatobiliary, bone spots and other small organ studies.

The company also announced the first installations for the device at two leading acute care hospitals, Meritus Medical Center in Hagerstown, Md. and St. Barnabas Medical Center in Livingston, N.J.

The image quality and low lifetime system cost, offers medium to large hospitals and imaging centers a cost-effective tool to expand volume, improve efficiency and provide quality patient care.

Commercially available worldwide, the camera provides high-quality imaging capabilities and the freedom to perform long duration time/activity studies. Its minimized focal distance and mm/pixel ratio maximizes diagnostic quality through improved image resolution. The results of this combination are increased operating efficiency, better imaging economics and improved diagnostic results.

It requires less than 8 square feet of floor space, and features a 6-inch field of view and lightweight collimators, which are easily changed by hand. Its unobtrusive design promotes patient comfort and is non-claustrophobic.

The system works in conjunction with the NuQuest acquisition and processing computer, providing a comprehensive, standalone system. The onboard NuQuest computer provides state-of-the-art energy, linearity and uniformity corrections for superior image quality. The software features customizable imaging acquisition protocols along with a host of general nuclear image processing tools. It also features an intuitive user interface with simple pull-down menus and features DICOM 3.0 print, file export and modality worklist capabilities.

For more information: www.medx-inc.com

Related Content

PET Tracer Gauges Effectiveness of Promising Alzheimer's Treatment

Longitudinal PET imaging with 18F-AV45. PET imaging shows the average 18F-AV45 uptake per animal group at 8 and 13 months of age. A significant interaction of genotype treatment was observed in the cortex (p = 0.0248), hippocampus (p = 0.0071) and thalamus (p = 0.0084), indicating reduced [18F]-AV45 uptake in BACE1 inhibited transgenic mice. Credit: MICA, University of Antwerp, Belgium.

News | Radiopharmaceuticals and Tracers | December 28, 2017
In the December featured basic science article in The Journal of Nuclear Medicine, Belgian researchers report on the...
Vital Unveils Newest Vitrea Advanced Visualization Release at RSNA 2017
Technology | Advanced Visualization | December 04, 2017
Vital Images unveiled the newest version of Vitrea Advanced Visualization software, the cornerstone of its imaging...
Michael J. Fox Foundation and Tau Consortium Developing PET Tracers for Neurodegenerative Disease
News | Radiopharmaceuticals and Tracers | October 27, 2017
The Michael J. Fox Foundation for Parkinson's Research (MJFF) and the Tau Consortium announced a funding partnership to...
Netherlands Cancer Institute Exploring Molecular Imaging Technology for Prostate Cancer Surgery
News | Molecular Imaging | October 26, 2017
The Netherlands Cancer Institute (NKI) announced it has received funding from the Dutch Cancer Society (KWF...
SNMMI Publishes New FDG PET/CT Appropriate Use Criteria
News | PET-CT | October 25, 2017
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has published appropriate use criteria (AUC) for FDG PET/...
Biodex Unveils Atomlab 500 Dose Calibrator and Wipe Test Counter
Technology | Nuclear Imaging | October 19, 2017
Biodex Medical Systems announced the full release of the Atomlab Dose Calibrator and Wipe Test Counter to the market...
ASNC and ASE Team Up to Expand ImageGuide Registry
News | Cardiovascular Ultrasound | October 12, 2017
The American Society of Nuclear Cardiology (ASNC) and the American Society of Echocardiography (ASE) jointly announced...
MR Solutions Showcases Multimodality MRI Solutions on Two Continents
News | Magnetic Resonance Imaging (MRI) | October 11, 2017
October 11, 2017 — MR Solutions took their cryogen-free preclinical multimodality...
Majority of Recurrent Prostate Cancer Patients' Treatment Plan Changed Following Fluciclovine 18F PET/CT
News | Prostate Cancer | October 04, 2017
Blue Earth Diagnostics recently announced the results of a pre-planned interim analysis from an investigational...
News | Business | September 19, 2017
September 19, 2017 — Invicro LLC, a provider of imaging services and software for research and drug development, anno
Overlay Init